The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
Notice for osimertinib (AstraZeneca Pty Ltd)
Active ingredients
osimertinib
Sponsor
Date of review outcome
Lapse date
Type
Priority Review
Dosage form(s)
Tablet
Indication
For the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations
Registration date